Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
SunEWdeFontgalland DRabbittPHollingtonPSposatoLDueSLet al
CTL, control
Pickart L, Vasquez-Soltero JM, Margolina A
The expanding treatment eligibility criteria and increasing willingness of payers to cover GLP-1 medications are driving accelerated market growth
However, the pharmacological and surgical treatments selected as medical interventions should be individualized based on an understanding of each individuals cause of obesity and characteristics
The study evaluated Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, as an adjunct to standard of care for prevention of MACE in patients with established CVD who were overweight or obese with no prior history of diabetes over a period of 5 years
US$ 23.16
US$ 22.52
US$ 27.54
US$ 26.30
US$ 27.95
US$ 25.30
